A 75-year-old man with adenocarcinoma and PD-L1 TPS 25–49% was initially treated with Pembrolizumab obtaining PR but it was prematurely discontinued due to tubulo-interstitial nephritis; at disease progression he was rechallenged with Atezolizumab obtaining a response which has been sustained for more than 15 months without recurrence of nephritis [134]. This evidence concerns the gene CD274 and adenocarcinoma.